Publication | Closed Access

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

HypertensionPulmonary Arterial HypertensionCardiovascular DiseaseExperimental Pulmonary HypertensionPharmacologyPulmonary PharmacologyPublic HealthMedicinePrevents ProgressionPulmonary Vascular Disease